Fig. 2: Relationship between the sensitivity of anti-PD-1 antibody therapy and tumor microenvironment. | Nature Communications

Fig. 2: Relationship between the sensitivity of anti-PD-1 antibody therapy and tumor microenvironment.

From: Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 therapy

Fig. 2

a Volcano plots showing differential gene expression in the tumor tissues of anti-PD-1 antibody-responsive and nonresponsive mice. (n = 3 mice per group; two-tailed Student’s t-test for comparison using Cuffdiff in the Cufflinks package). b Top 20 enrichment ratios (E-ratio) in GO term enrichment analysis of differentially expressed genes in tumor tissues of anti-PD-1 antibody-responsive and nonresponsive mice. (n = 3 mice per group; one-sided hypergeometric test). c GO enrichment analysis of the differentially expressed genes associated with macrophages, T cells and antigen presentation pathways in tumor tissues of anti-PD-1 antibody-responsive and nonresponsive mice. (n = 3 mice per group; one-sided hypergeometric test). d–k The numbers of CD80+ TAMs (d), CD86+ TAMs (e), CD206+ TAMs (f), CD8+ T (g), CD8+IFNγ+ T (h), CD8+PD-1+ T (i), CD8+PD-1+TCF-1+ T (j), and CD8+PD-1+TCF-1- T (k) cells in tumor tissues of orthotopic Hepa1-6 tumor-bearing mice after intraperitoneal injection of PBS or anti-PD-1 antibody at the dosage of 5 mg kg−1 every four days for 5 times indicated in Supplementary Fig. 1a. Data are presented as means ± s.d. (n = 5 mice for control group, n = 11 mice for anti-PD-1 nonresponsive group, n = 12 mice for anti-PD-1 responsive group; one-way ANOVA followed by Tukey’s HSD post-hoc test). Source data are provided as a Source Data file.

Back to article page